Disease | epidermolysis bullosa |
Phenotype | C0007137|squamous cell carcinoma |
Sentences | 9 |
PubMedID- 25506404 | Polymeric nanoparticles to combat squamous cell carcinomas in patients with dystrophic epidermolysis bullosa. |
PubMedID- 20586780 | Background: tumour-specific expression of matrix metalloproteinase (mmp)-7 has been noted in cutaneous squamous cell carcinomas (sccs) in patients with recessive dystrophic epidermolysis bullosa (rdeb). |
PubMedID- 26302137 | This article summarizes recommendations reached following a systematic literature review and expert consensus on the diagnosis and management of cutaneous squamous cell carcinomas in people with epidermolysis bullosa. |
PubMedID- 25022710 | squamous cell carcinoma in a patient with dystrophic epidermolysis bullosa: a wound management strategy. |
PubMedID- 22564523 | Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. |
PubMedID- 19760773 | While its most severe variant, dystrophic epidermolysis bullosa (deb) is associated with squamous cell carcinoma (scc), the development of extracutaneous neoplasms in ebs is extremely rare. |
PubMedID- 25758658 | Electrochemotherapy, a potential new treatment for the management of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: report of three cases. |
PubMedID- 24960768 | Subcutaneous spreading squamous cell carcinoma in a patient with epidermolysis bullosa. |
PubMedID- 23398414 | Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. |
Page: 1